

Supplementary Table S2. Immunohistochemical and molecular features of the 15 cases

sAC	TTF1	Napsin A	P40	CK 5/6	CHR	SYNP	CD56	ALK	ROS1	PD- L1	NGS
Case 1	+	X	-	X	X	X	X	-	-	-	<i>KRAS</i> mutation
Case 2	+	X	-	X	X	X	X	X	X	X	X
Case 3	+	+	X	X	X	X	X	X	X	X	X
Case 4	+	-	-	-	-	-	+	-	-	TPS: 75%	-
Case 5	+	X	-	X	X	X	X	X	X		X
SCC											
Case 1	-	-	+	+	-	-	X	X	X	X	X
Case 2	-	X	+	X	X	X	X	X	X	-	-
Case 3	-	-	+	+	+	-	-	-	-	TPS: 90%	-
Case 4	-	-	+	X	-	-	+	X	X	X	X
Case 5	-	X	+	X	X	X	X	X	X	X	X
CaT											
Case 1	+	X	-	-	+	+	+	X	X	X	X
Case 2	+	X	-	X	+	+	+	X	X	X	X
Case 3	-	X	X	X	+	+	+	X	X	X	X
Case 4	+	X	X	X	+	+	X	X	X	X	X
Case 5	-	X	X	X	+	+	+	X	X	X	X

X, not applied; +, positive; -, negative.

sAC, solid adenocarcinoma; TTF1, thyroid transcription factor 1; CK 5/6, cytokeratin 5/6; CHR, chromogranin; SYNP, synaptophysin; ALK, anaplastic lymphoma kinase; ROS1, ROS proto-oncogene 1; PD-L1, programmed death-ligand 1; NGS, next-generation sequencing; *KRAS*, Kirsten rat sarcoma virus; TPS, tumor proportion score; SCC, squamous cell carcinoma; CaT, carcinoid tumor.